Nanomedicine News

RSS
EC Approves ABRAXANE Plus Gemcitabine for Treatment of Metastatic Pancreatic Cancer

EC Approves ABRAXANE Plus Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Nanotechnology and Immunology Used to Raise Tumor-Hunting Immune Cells to Attack Neuroblastoma

Nanotechnology and Immunology Used to Raise Tumor-Hunting Immune Cells to Attack Neuroblastoma

Engineered Nanoparticles May Enable On-Demand Vaccines

Engineered Nanoparticles May Enable On-Demand Vaccines

Kala Seeks FDA IND Approval for MPP-Formulated Loteprednol Etabonate Ophthalmic Nano-Suspension Phase 3 Clinical Program

Kala Seeks FDA IND Approval for MPP-Formulated Loteprednol Etabonate Ophthalmic Nano-Suspension Phase 3 Clinical Program

Novel Nanoparticles Carry Different Cancer-Killing Drugs and Deliver Them to Different Locations

Novel Nanoparticles Carry Different Cancer-Killing Drugs and Deliver Them to Different Locations

Astellas and ClearPath Partner to Build Global Franchise for Nanoparticle-Based RSV Vaccine

Astellas and ClearPath Partner to Build Global Franchise for Nanoparticle-Based RSV Vaccine

Immunovative Therapies Provides Comprehensive Update to Tauriga

Immunovative Therapies Provides Comprehensive Update to Tauriga

Nanonetwork Simulator for Validating Communication Theoretical Models for Nervous System

Nanonetwork Simulator for Validating Communication Theoretical Models for Nervous System

Scientists Inject Nanoparticles Carrying RNA Gene-Silencing Snippet to Treat Breast Cancer

Scientists Inject Nanoparticles Carrying RNA Gene-Silencing Snippet to Treat Breast Cancer

Researchers Develop Noninvasive Vapor Nanobubble Technology for Diagnosis of Malaria

Researchers Develop Noninvasive Vapor Nanobubble Technology for Diagnosis of Malaria

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.